A Study to Assess the Safety and Efficacy Of Tafamidis In Chinese Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
NCT04814186
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
53
Enrollment
INDUSTRY
Sponsor class
Conditions
Transthyretin Amyloid Cardiomyopathy
Interventions
DRUG:
Tafamidis
Sponsor
Pfizer